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PGS2
ECONOMIC BURDEN OF IBS
Badia X1, Mearín F2, Caballero AM3, Díaz-Rubio M4,
Domínguez E4, Garrigues V5, Pique J6, Cucala M7,
Espinosa C7, Balañà M7, Roset M1
1Health Outcomes Research Europe, Barcelona, Spain;
2Centro Médico Teknon, Barcelona, Spain; 3Universidad de
Granada, Granada, Spain; 4Hospital Clínico San Carlos, Madrid,
Spain; 5Hospital la Fé,Valencia, Spain; 6Hospital Clínic,
Barcelona, Spain; 7Excelent, Barcelona, Spain
OBJECTIVE: Compare the resource use between IBS
patients and non-IBS subjects (controls), in order to esti-
mate the burden of IBS. METHODS: Observational,
prospective study including a sample of 455 IBS patients,
meeting Rome II criteria, and 69 controls. The controls
were selected from those subjects who had attended a
health centre with a relative due to digestive problems
(excluding IBS). Both samples were selected from the 
consulting rooms of 86 Spanish gastroenterologists and
physicians. Patients and controls attended a total of ﬁve
visits at three-month intervals, making a total follow-up
period of one year. During the ﬁrst month after each visit
patients completed a diary including information about
resource use. Indirect resources and drugs use were reg-
istered in the patients’ diary and other direct resources
were registered in follow-up medical controls. RESULTS:
The results presented are preliminary and corresponding
to prospective information obtained from the ﬁrst 3
months’ follow-up. The patients mean (SD) age was 43
(14) years and 76.5% were female. Patients and controls
were of the same age and gender. 52.6% of IBS patients
and 29% of controls visited a clinic at least ones (p <
0.01), 2% of patients were hospitalised and 14.2% of
patients visited an emergency ward at least ones. The cost
associated with resources used was almost three times
higher in patients than in controls (p < 0.01). In terms of
indirect resources, 35.8% of patients and 20% of con-
trols experienced limited or reduced performance at work
during the month following the baseline visit (p < 0.05).
The mean cost associated with absence from work at one
month was also higher for patients (€100.34) than for
controls (€37.12) (p < 0.01). CONCLUSIONS: IBS is
associated with an important burden in terms of direct
and indirect costs, IBS patients using more health
resources and experiencing a higher productivity loss.
PGS3
HEALTH CARE RESOURCE UTILIZATION AND
COSTS OF TREATING NSAID-ASSOCIATED
GASTROINTESTINAL TOXICITY IN JAPAN:
FEASIBILITY OF A DELPHI-PANEL APPROACH
IN JAPAN
Kamae I1,Yanagisawa S1,Aino H1, Niimi S2
1Kobe University, Kobe, Japan; 2Social Survey Research
Information Co., Ltd,Tokyo, Japan
OBJECTIVE: Using a Delphi panel method, this study
determined and evaluated the clinical treatment patterns
of moderate-to-severe gastrointestinal (GI) events associ-
ated with NSAIDs in Japan. METHODS: Two resource
utilization questionnaires were originally developed in
English for a similar survey in the US and Europe (one
for GI events requiring hospitalization and another for
those not requiring hospitalization). The questionnaires
were translated and culturally adapted for Japan and a
pilot test was conducted. For the full survey, a Delphi-
panel method was used. RESULTS: The pilot test of 
the translated/culturally-adapted questionnaires indicated
that the instruments could feasibly be adapted for use in
Japan. Missing data was only 4% in the pilot test. For
the Delphi panel, 30 specialists were contacted to parti-
cipate (10 rheumatologists and 20 gastroenterologists).
Physicians were interviewed separately face-to-face,
answers were summarized across all participants and the
summary results were presented to each participant at 
a second face-to-face meeting. Participants could then
modify their original answers. Average resources and
costs required for the treatment and follow-up of GI
events will be summarized. CONCLUSION: A lack of
observational databases in Japan makes identiﬁcation of
treatment patterns and thus resource utilization estimates
quite difﬁcult. Interviewing experts about their treatment
patterns using a Delphi panel approach appears to be a
feasible option in Japan; individual face-to-face inter-
views are recommended. Cultural adaptation of ques-
tionnaires (originally developed for use outside of Japan)
was necessary as the design of questionnaires and the
structure of questions in Japan is somewhat different.
Additionally, modiﬁcation of the target specialist physi-
cians was necessary due to the different referral patterns
found in Japan.
PGS4
LOW-DOSE PPI AND STANDARD-DOSE PPI
COMPARED WITH H2RA FOR MAINTENANCE
THERAPY OF GERD—A COST-EFFECTIVENESS
ANALYSIS USING MARKOV MODEL
You JH, Lee AC,Wong SC, Chan FK
The Chinese University of Hong Kong, Hong Kong, China
OBJECTIVES: To evaluate the cost-effectiveness of three
treatment strategies for maintenance therapy of gastroe-
sophageal reﬂux disease (GERD) from the perspective of
a public health organization in Hong Kong. METHODS:
A Markov model was designed to simulate, over 12
months, the resource utilization and clinical outcomes of
GERD patients with healed esophagitis associated with
three treatment alternatives: Standard-dose H2-receptor
antagonist (H2RA), low-dose proton-pump inhibitor
(PPI) and standard-dose PPI. Patients who experienced
relapse of GERD on H2RA or low-dose PPI would be
stepped-up to standard-dose PPI. Relapse occurred during
maintenance therapy with standard-dose PPI would be
treated by high-dose PPI. The probabilities of relapse
were derived from literature. Resource utilization for
maintenance and active treatment of GERD were
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retrieved from the medical records of a group of GERD
patients in Hong Kong. Sensitivity analysis was 
conducted to examine the robustness of the model.
RESULTS: The cost-effectiveness ratios (CERs) of 
standard-dose H2RA, low-dose PPI and standard-dose
PPI per asymptomatic patient-month were HKD644, 660
and 873, respectively (1USD = 7.8HKD). The incremen-
tal CER (ICER) of low-dose PPI comparing to standard-
dose H2RA was HKD1,241 per additional asymptomatic
patient-month gained, while the ICER of standard-dose
PPI comparing to low-dose PPI was HKD11,766 per
additional asymptomatic patient-month gained. One-way
sensitivity analysis showed that the CER of standard-dose
PPI was insensitive to variation of all the inputs of the
model. The CERs of low-dose PPI and standard-dose
H2RA were sensitive to the variation of relapse rate of
H2RA and direct medical cost per symptomatic patient-
month. CONCLUSION: Based on the Markov analysis
of the data obtained, standard-dose PPI was more expen-
sive but more effective than low-dose PPI or standard-
dose H2RA for maintenance treatment of patients with
GERD.
PGS5
A COST-EFFECTIVENESS ANALYSIS OF
ESOMEPRAZOLE VS. OMEPRAZOLE IN THE
ACUTE TREATMENT OF PATIENTS WITH
REFLUX OESOPHAGITIS IN GREECE
Karokis A1, Christodoulopoulou A1,Wahlqvist P2
1AstraZeneca SA, Athens, Greece; 2AstraZeneca R&D
Mölndal, Mölndal, Sweden
OBJECTIVE: To compare the cost-effectiveness of
esomeprazole 40mg od or omeprazole 20mg od in the
acute treatment of patients with reﬂux oesophagitis 
in Greece. METHODS: A simple decision analysis 
model was designed to compare the cost-effectiveness of
esomeprazole vs. omeprazole during eight weeks’ acute
treatment of reﬂux oesophagitis patients. Omeprazole,
the leading PPI in Greece, was chosen as the comparator.
Probability of treatment success was based on pooled
healing rates (Life Table estimates) from 3 clinical studies
(N = 4877). Only direct medical costs were included in
the cost-effectiveness analysis. As patients can unrestrict-
edly visit public or private sector GPs or gastroenterolo-
gists, all patients were assumed to visit a specialist. 
An endoscopy was assumed to be carried out in non-
responders after eight weeks’ of therapy, which is a con-
servative patient management assumption, according to
results obtained from a market research among Greek
gastroenterologists. Furthermore, the analysis did not
consider additional treatment costs (e.g. drugs, visits) for
failures beyond eight weeks. One analysis was carried 
out by using private market and one by using public hos-
pital endoscopy and visit charges. RESULTS: Healing
rates from the pooled analysis showed that esomeprazole
is signiﬁcantly more effective than omeprazole. After 4
weeks of therapy, healing rates were 77.7% for esomepra-
zole compared with 67.6% for omeprazole (p < 0.001).
The corresponding values after 8 weeks treatment were
93.4% and 86.2%, respectively (p < 0.001). The decision
analysis model resulted in similar direct medical costs for
the esomeprazole and the omeprazole strategy, both when
using public (€328 vs. €330) and private charges (€353
vs. €356). CONCLUSIONS: Despite using conservative
assumptions, esomeprazole 40mg od was found to be
cost-effective compared with omeprazole 20mg od in the
acute treatment of patients with reﬂux oesophagitis in
Greece, since esomeprazole provides better effectiveness
at no additional treatment costs.
PGS6
COST COMPARISON OF ESOMEPRAZOLE
BASED AND OMEPRAZOLE BASED
HELICOBACTER PYLORI ERADICATION
STRATEGIES IN DUODENAL ULCER DISEASE 
IN GREECE
Christodoulopoulou A1, Karokis A1,Wahlqvist P2
1AstraZeneca SA, Athens, Greece; 2AstraZeneca R&D
Mölndal, Mölndal, Sweden
The recommended Helicobacter Pylori (H. Pylori) eradi-
cation treatment strategy in duodenal ulcer (DU) disease
includes one-week proton pump inhibitor (PPI) triple
therapy regimens followed by PPI monotherapy for three
weeks. Triple therapy regimens of omeprazole, amoxi-
cillin and clarithromycin (OAC) are the most widely used
regimens in Greece. Esomeprazole, the ﬁrst PPI developed
as an optical isomer, has been shown to achieve greater
and more sustained acid control than omeprazole, with 
a similar tolerability and safety proﬁle. Results from 
two clinical studies reveal that eradication regimens 
with esomeprazole 1-week triple therapy (esomeprazole,
amoxicillin, clarithromycin) (EAC) without subsequent
three weeks monotherapy show comparable eradication
rates with OAC including 3 weeks monotherapy (EAC:
90%, n = 204, OAC: 88%, n = 196; EAC: 86%, n = 214,
OAC: 88%, n = 219). OBJECTIVE: To evaluate the
potential cost savings associated with eradication of H.
Pylori with EAC 1-week therapy compared with OAC 1-
week therapy followed by 3 weeks omeprazole monother-
apy in patients with DU in Greece. METHODS: Patient
management in clinical practice was investigated through
market research of 10 Greek gastroenterologists. A 
cost analysis was performed to assess incremental direct
medical costs associated with the esomeprazole and
omeprazole based eradication strategies. The perspective
of the analysis was that of the Greek health care system
(Greek public sector charges). RESULTS: The cost analy-
sis showed that eradication treatment with esomeprazole
therapy results in a cost per patient of €114,57 while
treatment with omeprazole results in a corresponding cost
per patient of €158,18. Thus, esomeprazole therapy 
provides cost savings of 28% (€43,6) per patient when
compared with omeprazole therapy. CONCLUSION:
Eradication of H. Pylori with 1-week triple therapy with
